Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Page E. Blas, Esther San Roman Rodriguez, Heather L. Williams, Maren K. Levin, Joshua S.K. Bell, Mariaelena Pierobon, Alexander S. Barrett, Emanuel F. Petricoin, Joyce A. O'Shaughnessy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2-positive breast cancer. Recent studies have also highlighted the presence of activating mutations in HER2, and HER3 that are predicted to enhance HER2 downstream pathway activation in a HER2-dependent manner. Methods: In this report, we present two exceptional responses in hormone receptor-positive, HER2-nonamplified, HER2/HER3 co-mutated metastatic breast cancer patients who were treated with the anti-HER2-directed monoclonal antibodies, trastuzumab and pertuzumab. Results: Both patients acheived exceptional responses to treatment, suggesting that combined trastuzumab, pertuzumab, and endocrine therapy could be a highly effective therapy for these patients and our observations could help prioritize trastuzumab deruxtecan as an early therapeutic choice for patients whose cancers have activating mutations in HER2.

Original languageEnglish
Article numbere1954
JournalCancer Reports
Volume7
Issue number3
DOIs
StatePublished - Mar 2024
Externally publishedYes

Keywords

  • cancer biology
  • exceptional responder
  • HER2/HER3 co-mutations
  • metastatic breast cancer

Fingerprint

Dive into the research topics of 'Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy'. Together they form a unique fingerprint.

Cite this